Gaenzle Christopher L 4

Accession 0001104659-21-082848

CIK 0001613859other

View on SEC.gov Company Profile

Filed

Jun 16, 8:00 PM ET

Accepted

Jun 17, 8:50 PM ET

Size

32.6 KB

Accession

0001104659-21-082848

Insider Transaction Report

Form 4

Period: 2021-06-15

PRA Health Sciences, Inc.PRAH

Gaenzle Christopher L

EVP, Chief Admin Officer & GC

Transactions

Exercise/Conversion
Stock Options (Right to Buy)
2021-06-15−1,984→ 23,686 total
Exercise: $103.30Exp: 2030-06-01→ Common Stock (1,984 underlying)
Exercise/Conversion
Common Stock
2021-06-16$101.42/sh+9,844$998,378→ 44,344 total
Exercise/Conversion
Common Stock
2021-06-16$95.94/sh+2,188$209,917→ 46,532 total
Sale
Common Stock
2021-06-16$167.49/sh−500$83,745→ 34,500 total
Exercise/Conversion
Stock Options (Right to Buy)
2021-06-15−8,698→ 66,302 total
Exercise: $101.42Exp: 2028-08-10→ Common Stock (8,698 underlying)
Exercise/Conversion
Stock Options (Right to Buy)
2021-06-16−9,844→ 56,458 total
Exercise: $101.42Exp: 2028-08-10→ Common Stock (9,844 underlying)
Exercise/Conversion
Common Stock
2021-06-15$101.42/sh+8,698$882,151→ 45,171 total
Exercise/Conversion
Common Stock
2021-06-15$103.30/sh+1,984$204,947→ 49,088 total
Sale
Common Stock
2021-06-15$168.27/sh−14,386$2,420,732→ 34,702 total
Exercise/Conversion
Common Stock
2021-06-16$103.30/sh+2,246$232,012→ 48,778 total
Sale
Common Stock
2021-06-16$166.48/sh−13,778$2,293,761→ 35,000 total
Exercise/Conversion
Stock Options (Right to Buy)
2021-06-16−2,188→ 20,879 total
Exercise: $95.94Exp: 2029-08-13→ Common Stock (2,188 underlying)
Exercise/Conversion
Stock Options (Right to Buy)
2021-06-16−2,246→ 21,440 total
Exercise: $103.30Exp: 2030-06-01→ Common Stock (2,246 underlying)
Exercise/Conversion
Common Stock
2021-06-15$95.94/sh+1,933$185,452→ 47,104 total
Sale
Common Stock
2021-06-15$168.83/sh−202$34,104→ 34,500 total
Exercise/Conversion
Stock Options (Right to Buy)
2021-06-15−1,933→ 23,067 total
Exercise: $95.94Exp: 2029-08-13→ Common Stock (1,933 underlying)

Footnotes (8)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $167.76 to 168.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2), (3), (4) and (5) to this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $168.76 to $168.87, inclusive.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $166.07 to $167.01, inclusive.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $167.23 to $167.86, inclusive.
[F6]The option vests in four equal annual installments of 18,750 beginning on August 10, 2019.
[F7]The option vests in three equal annual installments of 8,334 beginning on August 13, 2020.
[F8]The option vests in three equal annual installments of 8,556 beginning on June 1, 2021.

Documents

1 file

4
tm2120078d3_4seq1.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

PRA Health Sciences, Inc.

CIK 0001613859

→

Entity typeother

Related Parties

filerCIK 0001624044

Filing Metadata

Form type: 4
Filed: Jun 16, 8:00 PM ET
Accepted: Jun 17, 8:50 PM ET
Size: 32.6 KB

View on SEC.gov